Merck goes lean; McKesson to deliver H1N1 vaccine;

> A new supply strategy intended to yield a "leaner, more cost-able and buyer-focused manufacturing model" at the Merck Manufacturing Division is the goal of an international restructuring program. Announcement

> The CDC is upping its reliance on McKesson. The big-three drug distributor's assignment now includes delivery of H1N1 vaccine to some 90,000 sites, in addition to the distribution of public-sector purchased adult and pediatric vaccines. Release

> Analysis of novel marine microbes could lead to more efficient and greener ways to manufacture drugs. Release

> A new version the EudraGMP database provides public access to information about manufacturing, importation authorizations and good manufacturing practice certificates. Release

> As Caraco learns of another class action lawsuit filed against it for misleading investors concerning GMP lapses, an investment advisory concern finds the company "underappreciated and undervalued." Story

Suggested Articles

Teva will produce its new migraine drug at a plant in Israel and more news of note.

The shortage of childhood cancer drug vincristine was front and center during the Senate hearing for Stephen Hahn, nominee for FDA commissioner.

The FDA has lambasted the Torrent Pharmaceuticals in a warning letter for making OTC meds using water tainted with bacteria.